Details
Title
Author Correction: Proteostatic reactivation of the developmental transcription factor TBX3 drives BRAF/MAPK-mediated tumorigenesis
Author
Zhang, Zhenlei 1 ; Wu, Yufan 1 ; Fu, Jinrong 2 ; Yu, Xiujie 3 ; Su, Yang 4 ; Jia, Shikai 1 ; Cheng, Huili 1 ; Shen, Yan 3 ; He, Xianghui 5 ; Ren, Kai 6 ; Zheng, Xiangqian 7 ; Guan, Haixia 2
; Rao, Feng 4
; Zhao, Li 8
1 Tianjin Medical University, Department of Thyroid and Neck Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, National Clinical Research Center for Cancer, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228)
2 Southern Medical University, Department of Endocrinology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471)
3 Tianjin Central Hospital of Gynecology and Obstetrics, Department of Pathology, Tianjin, China (GRID:grid.410626.7) (ISNI:0000 0004 1798 9265)
4 Southern University of Science and Technology, School of Life Sciences, Shenzhen, China (GRID:grid.263817.9) (ISNI:0000 0004 1773 1790)
5 Tianjin Medical University, Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228)
6 Tianjin Medical University Cancer Institute and Hospital, Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, National Clinical Research Center for Cancer, Tianjin, China (GRID:grid.411918.4) (ISNI:0000 0004 1798 6427)
7 Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Department of Thyroid and Neck Tumor, Tianjin, China (GRID:grid.411918.4) (ISNI:0000 0004 1798 6427)
8 Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, National Clinical Research Center for Cancer, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Department of Thyroid and Neck Tumor, Tianjin, China (GRID:grid.263817.9)
; Rao, Feng 4
; Zhao, Li 8
1 Tianjin Medical University, Department of Thyroid and Neck Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, National Clinical Research Center for Cancer, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228)
2 Southern Medical University, Department of Endocrinology, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471)
3 Tianjin Central Hospital of Gynecology and Obstetrics, Department of Pathology, Tianjin, China (GRID:grid.410626.7) (ISNI:0000 0004 1798 9265)
4 Southern University of Science and Technology, School of Life Sciences, Shenzhen, China (GRID:grid.263817.9) (ISNI:0000 0004 1773 1790)
5 Tianjin Medical University, Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China (GRID:grid.265021.2) (ISNI:0000 0000 9792 1228)
6 Tianjin Medical University Cancer Institute and Hospital, Department of Radiation Oncology, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, National Clinical Research Center for Cancer, Tianjin, China (GRID:grid.411918.4) (ISNI:0000 0004 1798 6427)
7 Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Department of Thyroid and Neck Tumor, Tianjin, China (GRID:grid.411918.4) (ISNI:0000 0004 1798 6427)
8 Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, National Clinical Research Center for Cancer, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Department of Thyroid and Neck Tumor, Tianjin, China (GRID:grid.263817.9)
Pages
4936
Publication year
2024
Publication date
2024
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3066163049
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.